Compare Charles River Laboratories Intl. Inc (CRL) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs ING Groep NV — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while ING Groep NV trades at $32.76 (market cap $93.58B). The key difference: ING Groep NV is far larger — about 8.4× Charles River Laboratories Intl. Inc's market cap, and ING Groep NV pays a 3.86% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | ING | |
|---|---|---|
Market Cap | $11.14B | $93.58B |
Sector | Health | Financials |
52-Week High | $233.60 | $32.96 |
52-Week Low | $145.57 | $22.45 |
Enterprise Value | $14.00B | — |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
ING trades at $32.30, down 0.28% on the day, with strong analyst support (62.5% buy ratings) and bullish technical signals. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.63 exceeding the $0.60 forecast. Revenue growth remains steady at $22.9B for 2025, while net income margin stands at 27.84%. Recent corporate developments include a new global subscription banking model and management board appointments.
The outlook remains positive given ING's earnings momentum, attractive valuation (P/E 12.95), and strategic initiatives. Key risks include negative operating cash flow trends and exposure to European banking sector volatility. With intrinsic value estimates around $34 from DCF analyses, the stock offers potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
